Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences Inc. (formerly DanDrit Biotech USA, Inc.) on March 6, 2018, covering events occurring on February 28, 2018, and March 2, 2018. The company is a Delaware corporation with principal executive offices in Horsholm, Denmark. The filing primarily addresses corporate governance changes and a legal name change.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific director compensation arrangements:
- Standard Director Compensation: $45,000 annual cash plus stock options valued at $45,000 (vesting over three years) for Carl Sandler, James Sapirstein, and Evelyn D'An.
- Scientific Advisory Board Representative: Ambassador Mark R. Dybul receives $20,000 annual cash plus stock options valued at $20,000.
- Special Compensation: Carl Sandler received $152,000 for past services to a subsidiary and is entitled to $10,000 per month for six months for consulting services.
Material Changes
The following material changes were reported:
- Board Expansion: The Board of Directors increased its size from 2 to 4 members on February 28, 2018, and subsequently from 4 to 6 members on March 6, 2018.
- New Appointments: Carl Sandler and Ambassador Mark R. Dybul were appointed as directors on February 28, 2018. James Sapirstein and Evelyn D'An were appointed as independent directors on March 6, 2018.
- Corporate Name Change: Effective March 2, 2018, the company changed its name from DanDrit Biotech USA, Inc. to Enochian Biosciences Inc.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future business performance. No specific risks or contingencies were disclosed in this report other than the standard disclosure that no other reportable transactions exist between the new directors and the registrant.
Investor Verification Checklist
- Verify the legal name change from DanDrit Biotech USA, Inc. to Enochian Biosciences Inc. in corporate registries.
- Confirm the total dilution impact of the stock option grants ($45,000 value per standard director, $20,000 for Ambassador Dybul) on existing shareholders.
- Review the "Agreement and Plan of Merger" referenced in the filing (filed January 18, 2018) to understand the context of Carl Sandler's $152,000 past service payment.
- Check subsequent filings for the company's first financial report under the new name to assess operational status.